Know Cancer

forgot password

A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors

Phase 1
18 Years
Open (Enrolling)
Advanced Solid Tumors

Thank you

Trial Information

A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors

This is an open-label, ascending-dose study of XMT-1107 administered intravenously over 90
minutes every 21 days (1 cycle). Blood sampling for PK analyses will be performed
immediately prior to dosing and after dosing. Adverse events will be graded according to
the National Cancer Institute (NCI) Common Terminology Criteria (CTC) version 4.0 (CTCAE

Inclusion Criteria:

- Patient must have a histological diagnosis of advanced solid tumor and must be
refractory to standard therapy or have no effective therapy.

- Measurable or evaluable disease.

- At least 42 days since administration of mitomycin or nitrosoureas and 28 days since
any other chemotherapy, investigational agent, and/or radiation therapy.

- Age ≥ 18 years old.

- Have the following laboratory values:

- Absolute neutrophil count (ANC) ≥ 1500 cells/mm3

- Platelet count ≥ 100,000 cells/mm3

- Hemoglobin ≥ 9 g/dL

- Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min
(Calculated by Cockroft and Gault method. Creatinine clearance (mL/min) =
(140-age) x weight (kg)/72 x (serum creatinine in mg/dL) = ml**/min (**for
females, multiply results by 0.85))

- Total bilirubin ≤ 1.5 mg/dL or ≤ upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times
the institutional upper limit of normal (ULN) or ≤ 5 times ULN of liver
metastases are present

- Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5 times the ULN

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.

- Life expectancy of at least 3 months.

- Signed informed written consent.

Exclusion Criteria:

- Known brain metastases (either currently or previously).

- Peripheral neuropathy ≥ Grade 2.

- Ataxia ≥ Grade 1.

- Cognitive disturbance ≥ Grade 1.

- History of seizures.

- Patients known to be human immunodeficiency virus (HIV) positive.

- Active infections requiring IV antibiotics or serious intercurrent illness, including
hepatitis B or C.

- Unstable angina, recent myocardial infarction (within the previous 6 months), or use
of ongoing maintenance therapy for life-threatening arrhythmia.

- Known hypersensitivity to this class of drugs.

- Pregnant or nursing women, women who are of childbearing potential and are not using
an effective method of either barrier or hormonal contraceptives. Men who are not
using an effective method of barrier contraceptive, or who would not be willing to
continue to use these effective methods for the duration of the study.

- Patients who have had a major surgical procedure (not including mediastinoscopy),
open biopsy, or significant traumatic injury ≤ 4 weeks prior to beginning treatment.

- Patients with proteinuria at screening as demonstrated by either:

1. urine protein creatinine (UPC) ratio ≥ 1.0 at screening OR

2. urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+
proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine
collection, and must demonstrate ≤ 1 g of protein/24 hours to be eligible)

- Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.

- Patients with history of hematemesis or hemoptysis (defined as having bright red
blood of ½ teaspoon or more per episode) ≤ 1 month prior to study enrollment.

- Inadequately controlled hypertension (defined as systolic blood pressure >140 mm
Hg and/or diastolic blood pressure > 90 mm Hg while on antihypertensive medications).
Initiation of antihypertensive agents is permitted provided adequate control is
documented at least 1 week prior to beginning study treatment.

- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or
recent peripheral arterial thrombosis) ≤ 6 months prior to Day 1 of treatment.

- History of stroke or transient ischemic attack ≤ 6 months prior to beginning

- Any prior history of hypertensive crisis or hypertensive encephalopathy.

- History of abdominal fistula or gastrointestinal perforation ≤ 6 months prior to Day
1 of beginning treatment.

- QTc interval > 470 milliseconds as calculated by Bazett's formula.

- Any issue that, in the opinion of the Investigator, would render the patient
unsuitable for study participation.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective of this study is to determine the maximum tolerated dose of XMT-1107 when given via IV once every three weeks.

Outcome Time Frame:

Adverse events are assessed during each treatment cycle.

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

March 2010

Completion Date:

September 2013

Related Keywords:

  • Advanced Solid Tumors
  • Dose escalation
  • XMT-1107
  • 1107
  • Tumor
  • Phase 1
  • Fumagillol
  • PHF
  • Fleximer
  • cancer
  • maximum tolerated dose
  • MTD
  • Neoplasms



Dana Farber Cancer Institute (DFCI) Boston, Massachusetts  02215
Sarah Cannon Research Institute (SCRI) Nashville, Tennessee  37203
University of MD Greenbaum Cancer Center Baltimore, Maryland  21201
Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts  02215